Facilitating Collaborations to Develop Combination Investigational Cancer Therapies - Workshop Summary
||October 31, 2011
Note: Proceedings contain the opinion of the presenters, but do NOT reflect the conclusions of the Health and Medicine Division or the National Academies. Learn more about the differences between Reports and Proceedings.
Advances in biomedical research have increased our understanding of the complex nature of disease and the interaction of multiple molecular pathways involved in cancer. Combining investigational products early in their development is thought to be a promising strategy for identifying effective therapies, especially when a combination targets multiple pathways, providing greater benefit than a therapy directed at a single target.
The National Cancer Policy Forum convened a public workshop June 13-14, 2011 to examine the unique challenges involved in the development of combination investigational cancer therapies. The aims of the workshop were to identify barriers that may be preventing the development of combination investigational cancer therapies and to offer potential ways to overcome those barriers, with a focus on facilitating greater collaboration. Workshop presentations and discussions addressed scientific challenges and opportunities in the codevelopment of investigational therapies, the regulatory environment for codevelopment, and organizational culture and legal issues that may be influencing collaboration. This document is a summary of the workshop.